Skip to main content

Glans Reconstruction / Glansplasty

Glans reconstruction is an umbrella term for restoring contour and coverage after glans-preserving oncologic surgery, distal injury, or creation of a neoglans during phalloplasty. The indication determines the priority: cancer surgery requires oncologic staging and local control first; trauma and gender-affirming reconstruction require a separate, patient-specific reconstructive assessment.

The 2026 EAU-ASCO guideline strongly recommends offering organ-sparing surgery and reconstruction for PeIN, Ta, or T1–T2 lesions confined to the glans or prepuce when the patient is willing to comply with strict follow-up; wide local excision and partial or total glansectomy are options for selected glanular or coronal lesions.[1] The 2026 EAU-ASCO guideline strongly recommends informing patients that organ-sparing procedures and glanulopreputial epithelium-preserving techniques are associated with higher local-recurrence risk than amputative surgery; discussion of organ preservation and wider resection should account for tumour extent, function, and patient priorities.[1] NCCN Version 2.2026 lists complete glansectomy for selected PeIN or Ta tumors (category 2B), restricts glansectomy for pT1a to cases requiring it for complete clearance with negative margins (category 2A), and lists partial or total penectomy for T2 or greater disease (category 2A). These selection criteria differ from the EAU organ-sparing options for glans-confined cT1–T2 disease.[3][1]

Oncologic Reconstruction​

Clinical contextEvidence-bounded roleImportant limit
Extensive or recurrent PeINGlans resurfacing removes glandular epithelium and reconstructs the surface with a graft; it also provides a specimen for histopathology.[1]Suitability depends on clinical and pathological assessment, including cancer staging and margin planning.
Invasive disease confined to the glansWhen local excision or resurfacing is unsuitable, glansectomy with or without distal corporal resection and neoglans reconstruction may be considered.[1]Published glansectomy evidence is principally non-comparative and heterogeneous.
More extensive diseaseFor obvious cT3 cavernosal invasion, EAU describes partial penectomy as standard; MRI or ultrasound can aid planning when invasion is uncertain, and more radical surgery may be necessary if organ preservation cannot achieve safe margins.[1]—

EAU notes that a split-thickness skin graft is commonly used for neoglans reconstruction after glansectomy. NCCN describes STSG or FTSG reconstruction in selected instances and recommends frozen sections from the cavernosal bed and urethral stump to confirm negative margins (category 2A).[3] EAU-ASCO does not recommend routine frozen sections and recommends them when completeness of resection is in doubt .[1] A 2022 review of 20 mostly small single-centre studies reported local recurrence of 2.6–16.7%, graft loss of 1.5–23.5%, meatal stenosis of 2.8–14.3%, normal erections in 50–100% and good cosmesis in 95–100%.[1][2] A 2026 review identified 14 studies containing 327 glansectomies, but only five reported glansectomy separately; the other cohorts mixed procedures.[5]

Reconstructive Planning​

Planning should establish the diagnosis, defect depth, urethral involvement, oncologic requirements, tissue quality, and urinary, sexual and appearance goals. For a neoglans graft, assess poor vascular function, diabetes, immunosuppression and prior groin irradiation because the EAU guideline identifies these as graft-failure risks.[1] When graft failure risk is high, discuss primary closure as an alternative to a neoglans graft.[1] In cancer care, multidisciplinary assessment and scheduled surveillance are part of treatment. Counseling before organ-sparing surgery includes local recurrence risk; the EAU-ASCO 2026 guideline reports that local recurrence in higher-risk cohorts treated with radical glansectomy or partial penectomy was associated with poorer survival, possibly reflecting more aggressive tumor biology, and states that patients should be informed that wider resection (partial or radical penectomy) lowers local-recurrence risk at the cost of penile function.[1]

Outcomes and Follow-up​

Outcome reporting should remain indication-specific and include cancer control where relevant, graft healing, meatal/urethral complications, urinary function, erectile and sensory outcomes, appearance, patient-reported quality of life, and revision surgery. Existing studies use inconsistent definitions and follow-up.[1][2] After penile-preserving cancer treatment, the 2026 EAU follow-up table specifies primary-site examination every 3 months in years 1–2 and every 6 months in years 3–5; nodal surveillance depends on nodal status.[4] NCCN Version 2.2026 continues annual primary-site clinical examination in years 5–10 after topical or local therapy (category 2A).[3]

References​

1. European Association of Urology. EAU Guidelines on Penile Cancer: Disease Management. 2026. Available at: uroweb.org/guidelines/penile-cancer/chapter/disease-management. Accessed September 19, 2026.

2. Pang KH, Muneer A, Alnajjar HM. Glansectomy and reconstruction for penile cancer: a systematic review. Eur Urol Focus. 2022;8(5):1318–1322. doi:10.1016/j.euf.2021.11.008

3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Penile Cancer. Version 2.2026. June 5, 2026.

4. European Association of Urology. EAU Guidelines on Penile Cancer: Follow-up and Quality of Life. 2026. Guideline chapter.

5. Pang KH, Alnajjar HM, Muneer A. "Functional outcomes of glansectomy to treat localised penile cancer: a systematic review." Int J Impot Res. 2026;38(3):206–213. doi:10.1038/s41443-025-01062-1